ProQR Therapeutics initiated with Buy rating and $8 target by BofA
BofA analyst Alec Stranahan initiated coverage of ProQR Therapeutics with a Buy rating and a $8 price target, citing AX-0810 as first human validation of Axiomer and dose-dependent bile acid activity including up to an eight-fold rise in circulating total bile acids.